ArticleInternational journal of preventive medicine2025
Association of Pulmonary Symptoms and Co-Morbidity Diseases with Lung Function in Adult Smokers.
Article in International journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to evaluate the relationship of pulmonary symptoms and co-morbidity diseases with lung function in adult smokers. Methods: Three hundred and fifty men adults over the age of 20 were involved. Spirometry tests were performed for measuring FVC, FEV1, and FEV1% FVC. COPD was categorized into four stages (I-IV) by the (GOLD) criteria of post-bronchodilator FEV1/FVC <0.70. For comparing the mean of pulmonary functions regarding the following variables, pulmonary symptoms, and co-morbidity diseases, t-test was used. Spearman's correlation analysis was performed to get association between stages of COPD and study variables. Further analysis using multiple regressions was conducted to confirm the predictors of the pulmonary functions. The level of significance is taken as Results: The mean age of participants was 54.7543 ± 13.44. A total of 43 (19.5%) participants were COPD; 7% of them were Stage I, 23.3% were Stage II, 39.5% were Stage III, and 30.2% were Stage IV. The mean of FEV1 in participants with shortness of breath (P < 0.001), cough (P = 0.001), wheezing (P = 0.023), as well as cardiovascular disease (P = 0.038) was significantly less in compared to those without these symptoms and disease. Also the mean of FVC in participants with shortness of breath (P < 0.001) and cough (P = 0.029) was significantly less in compared to others. Finally, the mean of FEV1/FVC in participants with shortness of breath (P < 0.001), cough (P = 0.001), and wheezing (P = 0.01) was less. The relationship between stages of COPD and other variables indicated a significant association between stages of COPD and diabetes mellitus (β = -.342P = 0.030). According to linear regression model, shortness of breath was the only influential variable on FEV1 (B = -.383CI: -23.729, -12.155 Conclusions: Pulmonary symptoms including shortness of breath, cough, and wheezing influenced the lung function in adult smokers. Additionally, shortness of breath was associated with FEV1, FVC, and FEV1/FVC. Cardiovascular disease decreased FEV1 in smokers, whereas diabetes mellitus was associated with milder COPD stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.